ATOS

ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM) being developed for breast cancer risk reduction, neoadjuvant treatment, and metastatic breast cancer. The company has no current revenue-generating products and relies on cash reserves and potential future financing to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses increased by 45% ($2.9 million) for the three months ended September 30, 2025, compared to the same period in 2024. This was driven primarily by a 73% increase in clinical and non-clinical trial costs ($1.8 million increase) and higher professional fees related to regulatory consulting.
• Higher Net Loss: The net loss for the nine months ended September 30, 2025, increased to $23.8 million from $19.2 million in the prior year period. This reflects increased burn rate due to expanded clinical trial activities.
• Cash Position: Cash and cash equivalents decreased by approximately $19.2 million during the first nine months of 2025, compared to a decrease of $13.7 million in the same period of 2024.
• Impairment Charges: Unlike the prior year, which included a $1.7 million impairment charge on an investment in Dynamic Cell Therapies, Inc. (DCT), there were no impairment charges recorded in the current period.

Outlook, Risks, and Management Commentary

• Regulatory Strategy: Management is pursuing an accelerated regulatory path for low-dose (Z)-endoxifen for breast cancer risk reduction. The company received preliminary written comments from the FDA on November 6, 2025, and expects a meeting on November 17, 2025, to discuss a development plan for a potential New Drug Application (NDA).
• Clinical Progress:
  • Karisma Study: Top-line data for the Phase 2 study on mammographic breast density is expected in Q1 2026. Preliminary data showed significant density reduction at 1mg and 2mg doses.
  • EVANGELINE Study: The Phase 2 neoadjuvant study was amended to a single-arm, open-label design with a reduced patient count (40-65 patients) to focus on short-interval endpoints.
  • Metastatic Indication: The company received positive FDA feedback on a proposed global Phase 2 dose optimization trial for metastatic breast cancer, targeting an IND submission in Q4 2025.
• Liquidity: Management believes current cash resources ($51.8 million) are sufficient to fund operations for at least the next 12 months. However, the company will need to raise substantial additional capital in the future to continue development.
• Nasdaq Compliance: The company received a notice from Nasdaq regarding non-compliance with the minimum closing bid price requirement ($1.00). While the stock traded above $1.00 for 10 consecutive days post-period, Nasdaq exercised discretion to monitor compliance for an additional 10 days, during which the price did not remain above the threshold. The company has until February 17, 2026, to regain compliance.
• Legal Proceedings: Intas Pharmaceuticals Ltd. filed petitions to invalidate two of Atossa's patents (U.S. Patent Nos. 12,071,391 and 11,261,151). The PTAB granted institution of these reviews. Atossa intends to vigorously contest these petitions.
• Contingencies: A liability of $1.5 million is recorded regarding the Australian R&D tax incentive program, as the company is no longer reasonably assured the full tax position would be sustained under audit.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $51.8 million cash balance against the current burn rate of ~$6.4 million per quarter to confirm the 12-month liquidity assertion.
• Nasdaq Status: Monitor the stock price closely to ensure compliance with the $1.00 minimum bid price requirement by the February 17, 2026 deadline to avoid delisting.
• Patent Litigation: Track the outcome of the Post Grant Review (PGR) and Inter Partes Review (IPR) proceedings initiated by Intas Pharmaceuticals, as invalidation of patents could threaten the company's core IP.
• FDA Meeting Outcomes: Review the minutes from the November 17, 2025, FDA meeting to assess the feasibility of the proposed accelerated NDA pathway for low-dose (Z)-endoxifen.
• Australian Tax Liability: Monitor for any updates on the $1.5 million liability related to the Australian R&D tax rebate audit risk.